Better Bones
Human growth hormone
therapy improve bone density.
Treatment with human growth hormone affects several markers of bone formation, bone density and collagen turnover in healthy adults, according to new findings published in April 1999 issue of The Journal of Clinical Endocrinology and Metabolism.
The investigation examined the effects of HGH therapy on biochemical markers of bone and collagen turnover in 99 healthy volunteers. The subjects were randomized to either placebo or HGH, at 0.1 IU/kg per day, for 28 days, which was followed by a 56 day washout period.
Levels of all of the biochemical markers studied were increased relative to baseline and placebo in HGH-treated patients at 21 days. Many of these "HGH induced changes in the bone and collagen markers persist long after HGH withdrawal", the researchers found in particular, significant increases in procollagen type III and osteocalcin were still detected on the last day of the study. Another important study finding is that men are more sensitive than women to the effects of HGH on bone and collagen turnover.
The
substantial increase of bone density
remodeling achieved with human growth
hormone may be helpful during late menopause
with decreased bone turnover and impaired
osteoblastic function. Using growth hormone
to prevent physiological bone density loss
that occurs with age seems possible, but has
to be discussed on an ethical and economic
basis.
Excerpted
from Journal of HGH, Issue: Jan 15,2001.
Wuster C, Harle U, Muller C, Knauf K,
Koppler D, schwabe C, Ziegler R. Department
of Internal Medicine I-Endocrinology and
Metabolism, University Medical Clinic
Heidelberg, Germany. Article provided by the
National Library of Medicine.
22nd
Annual Meeting of the American Society for
Bone and Mineral Research
Day 1 - September 22, 2000
Treatment for Osteoporosis: New Drugs and
New Data on Old Drugs
Hgh Research by Ego Seeman, MD
There
is some HGH research evidence showing that
compounds such as human growth hormone or
insulin-like growth factor I (IGF-I) can
increase periosteal apposition, enlarging
bone and increasing its bending strength.
For example, Ammann and colleagues[34]
reported that IGF-1 increased periosteal
apposition, whereas pamidronate reduced
endocortical resorption. In addition, IGF-I
increased the external diameter of the
midshaft tibia and femoral neck.
Hermann and coworkers[35] studied the
effects of IGF-I and M-CSF on growing mouse
bone. Fifty 7-week-old male C57BL/6J mice
were assigned to placebo, IGF-I, M-CSF, or
both. M-CSF and the combination of IGF-I +
M-CSF increased bone strength. Elastic
strength increased by 14% (nonsignificant)
with IGF, 31% with M-CSF, and 35% with the
combination. Maximum strength increased by
9% (nonsignificant) with IGF, 23% with M-CSF,
and 22% with the combination. Whole bone
absolute masses were not altered, but
mineralization of the epiphysis increased by
4.4% with M-CSF and by 4.9% with the
combination. All treatments increased
diaphyseal mineralization compared with
placebo: 1.8% with IGF, 2.3% with M-CSF, and
2.9% with the combination. None of the
treatments increased bone formation rate.
Combined treatment increased periosteal
active mineralizing perimeter compared with
placebo (71%); the relative increase with M-CSF
alone was 47%. M-CSF and the combination
also had a greater effect on femoral
mechanical and compositional properties than
did IGF-I alone. The results suggest that M-CSF
can act as an anabolic agent, possibly
indirectly through coupled activation of
osteoblasts through osteoclasts. The hgh
research showed that combined use of IGF-I
and M-CSF may be more potent. More hgh
research taking such a specific structural
and biomechanical approach to the design and
evaluation of drug therapies is needed.
CLICK
HERE to take the next step for Ultimate
HGH
*Statements
contained herein have not been evaluated by the United States Food and
Drug Administration. These products are not intended to diagnose, treat
and cure or prevent disease.